Complementary and Alternative Medicine Use Was Associated With Higher Perceived Physical and Mental Functioning in Early Systemic Sclerosis

Explore: The Journal of Science and Healing

Volumn 4, Issue 4, 2008, Pages 259-263

  Hunnicutt, Sonya E ^a   Grady, James ^a   McNearney, Terry A ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

arthritis; CAM; GENISOS; GI hypomotility; integrative medicine; pain; scleroderma; SF 36

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; CALCIUM; CARNITINE; CHOLINE; CHONDROITIN SULFATE; CHROMIUM; CIMICIFUGA RACEMOSA EXTRACT; FISH OIL; FOLIC ACID; GARLIC EXTRACT; GINKGO BILOBA EXTRACT; GLUCOSAMINE; HERBACEOUS AGENT; IRON; MANGANESE; MINERAL; MOLYBDENUM; NUTRACEUTICAL; PHOSPHORUS; PHYTOESTROGEN; POTASSIUM; PRIMROSE OIL; SELENIUM; SULFUR; UBIDECARENONE; UNINDEXED DRUG; VITAMIN; VITAMIN B GROUP; ZINC;

ACUPUNCTURE; ADULT; AGED; ALTERNATIVE MEDICINE; ARTHRALGIA; ARTHRITIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DATA BASE; DEMOGRAPHY; DIFFUSE SCLERODERMA; DISEASE SEVERITY; DRUG MEGADOSE; ELECTROACUPUNCTURE; FATIGUE; FEEDBACK SYSTEM; FEMALE; GASTROINTESTINAL MOTILITY DISORDER; HEALTH INSURANCE; HUMAN; IMAGERY; MALE; MEDITATION; MENTAL FUNCTION; MOTIVATION; PAIN; PATIENT ATTITUDE; PATIENT COMPLIANCE; PHYSICAL CAPACITY; PRIORITY JOURNAL; QUALITY OF LIFE; RELAXATION TRAINING; SCORING SYSTEM; SELF CARE; SHORT FORM 36; SYMPTOM; SYSTEMIC SCLEROSIS; TRANSCUTANEOUS NERVE STIMULATION; UNITED STATES; YOGA;

ADULT; AGED; COMPLEMENTARY THERAPIES; FEMALE; FOLLOW-UP STUDIES; HEALTH BEHAVIOR; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; PAIN MEASUREMENT; QUALITY OF LIFE; QUESTIONNAIRES; SCLERODERMA, SYSTEMIC; SELF EFFICACY; TEXAS; TREATMENT OUTCOME;

EID: 46049115258     PISSN: 15508307     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.explore.2008.04.004     Document Type: Article

References (16)

1. Denton C.P., Black C.M., and Abraham D.J. Mechanisms and consequences of fibrosis in systemic sclerosis. Nat Clin Pract Rheumatol 2 (2006) 134-144
2. Soeken K.L. Selected CAM therapies for arthritis-related pain: the evidence from systematic reviews. Clin J Pain 20 (2004) 13-18
3. Breuer G.S., Orbach H., Elkayam O., et al. Perceived efficacy among patients of various methods of complementary alternative medicine for rheumatologic diseases. Clin Exp Rheumatol 23 (2005) 693-696
4. Rao J.K., Kroenke K., Mihaliak K.A., Grambow S.C., and Weinberger M. Rheumatology patients' use of complementary therapies: results from a one-year longitudinal study. Arthritis Rheum 49 (2003) 619-625
5. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 23 (1980) 581-590
6. Reveille J.D., Fischbach M., McNearney T., et al. Systemic sclerosis in 3 US ethnic groups: a comparison of clinical, sociodemographic, serologic, and immunogenetic determinants. Semin Arthritis Rheum 30 (2001) 332-334
7. Ware Jr. J.E., and Sherbourne C.D. The MOS 36-item short-form health survey (SF-36).I. Conceptual framework and item selection. Med Care 30 (1992) 473-483
8. Stewart A.L., Hays R.D., and Ware Jr. J.E. The MOS short-form general health survey. Reliability and validity in a patient population. Med Care 26 (1988) 724-735
9. Brennan P., Silman A., Black C., et al. Validity and reliability of three methods used in the diagnosis of Raynaud's phenomenon. The UK Scleroderma Study Group. Br J Rheumatol 32 (1993) 357-361
10. Clements P.J., Lachenbruch P.A., Seibold J.R., et al. Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J Rheumatol 20 11 (1993) 1892-1896
11. Medsger Jr. T.A., Bombardieri S., Czirjak L., et al. Assessment of disease severity and prognosis. Clin Exp Rheumatol 21 (2003) S42-S46
12. Del Rosso A., Boldrini M., Agostino D., et al. Health-related quality of life in systemic sclerosis as measured by the Short Form 36: relationship with clinical and biologic markers. Arthritis Rheum 51 (2004) 475-481
13. Danieli E., Paolo A., Lorenzo B., et al. Health-related quality of life measured by the Short Form 36 (SF-36) in systemic sclerosis: correlations with indexes of disease activity and severity, disability, and depressive symptoms. Clin Rheumatol 24 (2005) 48-54
14. Khanna D., Clements P.J., Furst D.E., et al. Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study. Arthritis Rheum 52 (2005) 592-600
15. Khanna D., Furst D.E., Clements P.J., et al., Relaxin Study Group. Scleroderma Clinical Trials Consortium. Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial. J Rheumatol 32 (2005) 832-840
16. Khanna D., Yan X., Tashkin D.P., et al., Scleroderma Lung Study Group. Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung study. Arthritis Rheum 56 (2007) 1676-1684